

Luteolin suppresses lipopolysaccharide-induced cardiomyocyte hypertrophy and autophagy *in vitro*

XING LI¹, JIAN LIU², JIANFENG WANG³ and DONGHUA ZHANG³

¹Teaching and Research Section of Traditional Chinese Medicine, Jiangsu Jiankang Vocational College, Nanjing, Jiangsu 210018;

²Department of Cardiovascular Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029; ³China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China

Received December 3, 2017; Accepted November 5, 2018

DOI: 10.3892/mmr.2019.9803

Abstract. Luteolin (LTL) serves essential roles in a wide variety of biological processes. Lipopolysaccharide (LPS) can lead to myocardial hypertrophy and autophagy. However, the roles of LTL on LPS-induced cardiomyocyte hypertrophy and autophagy in rat cardiomyocytes have not yet been fully elucidated. In the present study, the morphology of cultured rat cardiomyocytes was observed under an inverted microscope. Cell viability was detected by MTT assay. α -Actinin and microtubule-associated protein 1 light chain 3 (LC3) expression levels were measured by immunofluorescence assay. In addition, the expression levels of atrial natriuretic peptide/brain natriuretic peptide (ANP/BNP), LC3, and autophagy- and Wnt signaling pathway-associated genes were analyzed by reverse transcription-quantitative polymerase chain reaction or western blot assays. The results indicated that LTL increased the cell viability of cardiomyocytes treated with LPS. LTL decreased the expression of cardiac hypertrophy associated markers (ANP and BNP). LTL decreased α -actinin and LC3 expression levels in LPS-treated cardiomyocytes. It was also demonstrated that LTL suppressed the mRNA and protein expression levels of LPS-mediated autophagy and Wnt signaling pathway-associated genes. In addition, it was demonstrated that silencing of β -catenin inhibited LPS-induced cardiomyocyte hypertrophy and the formation of autophagosomes. Thus, the present study suggested that LTL protected against LPS-induced cardiomyocyte hypertrophy and autophagy in rat cardiomyocytes.

Introduction

Myocyte hypertrophy is one of the most important adaptive responses of the heart (1,2). The cardiomyocyte hypertrophy is characterized by enlarged myocardial cells and the accumulation of sarcomeric proteins (3,4). During this process, the myocardium irreversibly enlarges and expands, which is accompanied with apparent cardiac failure (5).

Lipopolysaccharide (LPS), a pathogen-associated molecular pattern, which can be found in the outer membrane of gram-negative bacteria (6), and can induce strong immune reaction (7). Previous studies have demonstrated that the mechanism of LPS-induced cardiac dysfunction is the activation of inflammation, or necrosis or cardiomyocyte apoptosis (8-10). LPS may couple with the Toll-like receptor 4, leading to cytoplasmic accumulation, nuclear translocation of β -catenin, target gene transcription and expression of myocardial hypertrophy genes (11,12).

Autophagy is a highly conserved lysosomal degradation pathway, of which there are three types: Chaperone-mediated autophagy, macroautophagy and microautophagy (13). Previous studies have demonstrated that autophagy is associated with many physiological and pathological processes; for example, cell development, immunity, infection, aging, cell survival, death and metabolism (14). Autophagy serves an important role in many critical human diseases, for instance, metabolic disorders, muscle atrophy, cancer, neurodegenerative and cardiovascular diseases (15-17). However, excessive autophagy can induce pathological diseases and autophagic cell death (18). A previous study has demonstrated that the suppression of excessive autophagy can relieve acute myocardial injury as well as accelerating rat model survival of LPS-induced cardiomyocyte contractile dysfunction (19).

Luteolin (LTL) is a type of natural flavonoids, and belongs to weak acid tetrahydroxy flavonoids (20). It has been demonstrated that flavonoids have a certain therapeutic effect on cardiovascular disease, by protecting the damaged myocardium (17,18,21,22). Moreover, LTL has a series of pharmacological effects, including anti-inflammatory, antioxidative, antitumor and antiviral (23-25). However, the effect of LTL on LPS-induced cardiomyocyte hypertrophy and the formation of autophagosomes are not fully understood.

Correspondence to: Dr Jian Liu, Department of Cardiovascular Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, 155 Hanzhong Road, Nanjing, Jiangsu 210029, P.R. China
E-mail: jianliu112@163.com

Key words: luteolin, lipopolysaccharide, cardiomyocyte hypertrophy, autophagy, cardiomyocytes

In the present study, the effect of LTL on LPS-induced viability of rat cardiomyocytes, and the effect of LTL on LPS-induced cardiomyocyte hypertrophy and the formation of autophagosomes was investigated. The regulatory effect of LTL on the expression level of β -catenin, was also investigated. In addition, β -catenin expression levels were silenced using small interference (si)RNAs in cardiomyocytes, and this effect on LPS-induced cardiomyocyte hypertrophy and formation of autophagosome was investigated.

Materials and methods

Source of drugs. LTL powder was obtained from Hangzhou Tiancao Technology Co., Ltd. (Hangzhou, China); the purity was >98%. LPS freeze-dried powder was purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China); the purity was >99%. The two powders were dissolved in DMSO and the solution was filtered with a 0.22 μ m membrane.

Cell culture. All animal experiments in the present study were approved by the animal ethics committee of Jiangsu Jiankang Vocational College. Hearts from Sprague Dawley (Nanjing Better Biotechnology Co., Ltd., Nanjing, China; <https://www.biomart.cn/46372/index.htm>) rats were used in single-cell cultures, as described previously (26). The rats (12 female, 3 male; age 8–10 weeks; average weight 300 g) had free access to water and food, and were maintained at 25°C, 12-h light/dark and 55–65% humidity. The neonatal rats were produced after the animals mated. Neonatal rats (n=5; age, 1–3 days) were used to isolate cardiomyocytes. The hearts were collected and minced into 1 mm³ sections. The pieces were dissociated with a buffer containing trypsin (0.05%) (Hyclone, Logan, UT, USA) and collagenase type II (0.4%) (Beijing Solarbio Science & Technology Co., Ltd) at 37°C for 30 min. The dissociation was stopped by the 5 min incubation of cold horse serum (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37°C. The isolated cells were cultured in Dulbecco's modified Eagle's medium/F12 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich; Merck KGaA). After three days, 0.1 mM bromodeoxyuridine (Sigma-Aldrich; Merck KGaA) was added into the medium to inhibit the growth of cardiac fibroblasts (27). Cells were cultured in a 90% humidified 37°C incubator with 5% CO₂. Finally, the morphology of the cultured rat cardiomyocytes was observed under inverted optical microscope (Nikon Corporation, Tokyo, Japan).

SiRNA transfection. siRNAs were commercially purchased from Thermo Fisher Scientific, Inc. The sequences of selected regions to be targeted by siRNAs for β -catenin were: 5'-UGG UUGCCUUGCUCACAAATT-3' (sense), 5'-UUGUUGAGC AAGGCAACCATT-3' (antisense). Cells (1x10⁵ cells/ml) were transfected with 50 nM scramble siRNA (Negative control, NC) or β -catenin-siRNA by Lipofectamine[®] 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot assays were performed to assess the transfection efficiency. Cells transfected into

β -catenin-siRNA were cultured for 24 h and then used for subsequent experiments.

Cell treatment. Cardiomyocytes (2.5x10³ cells/ml) were treated with 0.1% PBS (blank control group), 10% FBS (negative group, NC), LPS (100 ng/ml), LTL1 (50 mg/ml) and LPS (100 ng/ml), and LTL 2 (100 mg/ml) and LPS (100 ng/ml) for 8 h at 37°C. Subsequently, cells were used to detect the cell viability, the expression levels of α -actinin and LC3, and autophagy and Wnt signaling pathway-associated gene expression. Cardiomyocytes were treated with PBS, FBS, LPS, β -catenin siRNAs and LPS, and β -catenin siRNAs + LTL1 + LPS.

RT-qPCR assay. Total RNA was extracted from the treated cells using TRIzol[®] (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. First-strand cDNA was synthesized using Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc.). The mRNA expression levels were determined by qPCR using SYBR GREEN PCR Master Mix (Applied Biosystem; Thermo Fisher Scientific Inc.) and assayed by ABI 7500 Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific Inc.). The thermocycling conditions were set as follows: 10 min pretreatment at 95°C for 10 min, denaturation at 95°C for 15 sec, annealing at 61°C for 30 sec, extension at 72°C for 30 sec (40 cycles) and finally a 7-min extension at 72°C. The data were analyzed using 2^{- $\Delta\Delta$ C_q} method (28). The gene-specific primer sequences are listed in Table I; GAPDH was used as an internal loading control.

Western blot assay. Cells (5x10⁵ cells/ml) were lysed on ice in radioimmunoprecipitation assay buffer (cat. no. 8990; Pierce; Thermo Fisher Scientific, Inc.) buffer containing protease inhibitor cocktail (Thermo Fisher Scientific, Inc.). Pierce bicinchoninic Protein Assay kit (Thermo Fisher Scientific, Inc.) was applied to analyze the concentration of proteins. Total protein (30 μ g) was separated by 10% SDS-PAGE and then transferred onto polyvinylidene fluoride membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked with 5% skimmed milk and incubated with primary antibody overnight at 4°C. Next day, the membranes were as required incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:2,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or chicken anti-goat IgG-HRP (1:1,000; cat. no. sc-516086; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 2 h at room temperature. The protein expression levels were measured using an enhanced chemiluminescence system (Amersham Pharmacia Biotech; GE Healthcare, Chicago, IL, USA). The results were analyzed by Image Lab Software version 4.1 (Bio-Rad Laboratories, Inc.). Primary antibodies used were as follows: Anti-GAPDH (1:1,000; cat. no. sc-20358; Santa Cruz Biotechnology); anti-LC3 [two forms: LC3I and LC3II (29,30)]; 1:3,000; cat. no. ab64781; Abcam, Cambridge, UK); anti-Atg12 (1:1,000; cat. no. ab155589; Abcam), anti-autophagy-related 4b cysteine peptidase (Atg4b; 1:1,000; cat. no. 5299; Cell Signaling Technology, Inc., Danvers, MA, USA); anti-vacuolar protein sorting-associated protein 34 (Vps34; 1:1,000; cat. no. V9764; Sigma-Aldrich; Merck KGaA); anti-B cell lymphoma 2 interacting protein 1 (Bnip1; 1:300;

Table I. Primer sequences for the reverse transcription-quantitative polymerase chain reaction.

Gene	Primer sequences (5'-3')
GAPDH	F: TATGATGATATCAAGAGGGTAGT R: TGTATCCAACTCATTGTCATAC
LC3	F: GAGAAGCAGCTTCCTGTTCTGG R: GTGTCCGTTACCAACAGGAAG
BNP	F: TCGGCGCAGTCAGTCGCTTG R: CGCAGGCAGAGTCAGAAGCCG
ANP	F: TTCTCCATCACCAAGGGCTT R: GACCTCATCTTCTACCGGCA
Atg12	F: CAGAAACAGCCATCCAGAG R: GCCTTCAGCAGGATGTCAAT
Atg4b	F: TATGATACTCTCCGGTTTGCTGA R: GTTCCCCCAATAGCTGGAAG
Vps34	F: TGGAAGTGAATGAATGGC R: GCATCCCTTGCGGAAAC
Bnip1	F: GGAGGTGGAGGTTGTGATGA R: TATGGCAGCCCCTAGACATG
Wnt2	F: GGATGCCAGAGCCCCTGATGAATCTT R: GCCAGCCAGCATGTCCTGAGAGTA
β -catenin	F: GACTTCACCTGACAGATCCAAG R: AGCTGAACAAGAGTCCCAAG
GSK3 β	F: CTGGGACGACATGGAGAAAA R: AAGGAAGGCTGGAAGAGTGC

ANP, atrial natriuretic peptide; Atg, autophagy-related 4b cysteine peptidase; Bnip, B cell lymphoma 2 interacting protein; BNP, brain natriuretic peptide; F, forward; GSK3 β , glycogen synthase kinase 3 β ; LC3, microtubule-associated protein 1 light chain 3; R, reverse; Vps, vacuolar protein sorting-associated protein.

cat. no. sc-1713); anti-Wnt2 (1:300; cat. no. sc-50361; Santa Cruz Biotechnology, Inc.); anti-glycogen synthase kinase 3 β (GSK3 β ; 1:5,000; cat. no. ab32391; Abcam, Cambridge, UK) anti-phosphorylated-glycogen synthase kinase (p-GSK3 β ; 1:1,000; cat. no. 5558; Cell Signaling Technology, Inc.) and anti- β -catenin antibody (1:1,000; Abcam, cat. no. ab2982).

Cell viability assay. MTT assay was carried out to determine the cell viability. The treated cardiomyocytes (2×10^3 cells/well) were first seeded into 96-well plates and then cultured in cell incubators for 6 h at 37°C. After being cultured, 20 μ l solution MTT (5 mg/ml, cat. no. M-2128, Sigma-Aldrich; Merck KGaA) was added. After 4 h of incubation at 37°C, 10 μ l DMSO was added to dissolve the formazan product by incubating for 10 min at room temperature. Subsequently, the plates were measured by a microplate reader at 490 nm absorbance. Each condition was determined in quintuplicate from three independent experiments.

Immunofluorescence staining. The treated cardiomyocytes (3×10^4 cells/ml) were washed with PBS gently and then fixed with 4% paraformaldehyde at 4°C for 20 min. After blocking with 10% goat serum (Gibco™; cat. no. 16210064; Thermo

Fisher Scientific, Inc.), cells were incubated with primary antibodies anti- α -actinin (1:1,000; cat. no. ab9465; Abcam) and anti-LC3 (1 μ g/ml; cat. no. ab48394; Abcam) overnight at 4°C. After being washed, cells were incubated with a fluorescence-conjugated secondary antibody (4 μ g/ml; Alexa-Fluor® 594 goat anti-rabbit antibody IgG; A-11037; Thermo Fisher Scientific, Inc.) for 1 h at room temperature. Nuclei were counterstained with 4'-6-diamidino-2-phenylindole (DAPI; 1:1,000; Thermo Fisher Scientific, Inc.) for 15 min at 37°C, and the images were then obtained using a fluorescence microscope (Olympus Corporation, Tokyo, Japan). The cell surface area (green of fluorescence staining) was calculated by formula (axb)/2 (a: The longest distance through the nucleus; b: The shortest distance through the nucleus) and analyzed by Image Pro-Plus 6.1 software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis. All experiments were performed at least three times. Numerical data are shown as the mean \pm standard error. Statistical analysis was performed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) and statistical significance was assessed by analysis of variance with Dunnet's post-test comparison. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

LTL increases the viability of cardiomyocytes treated with LPS. To investigate the potential biological roles of LTL in cardiomyocytes, myocardial cells were isolated from newborn rats. The morphology of the cultured rat cardiomyocytes was observed with a microscope and most cells were typical myocardial cells (Fig. 1A). To determine the effect of LTL on cell viability, cardiomyocytes were treated with 0.1% PBS (blank control group), 10% FBS (negative group, NC), LPS alone (100 ng/ml), LTL1 (50 mg/ml) + LPS (100 ng/ml) and LTL 2 (100 mg/ml) + LPS (100 ng/ml) for 8 h. MTT assay was used to detect cell viability. The results indicated that LPS significantly decreased the viability of rat cardiomyocytes ($P < 0.001$), however, such an effect was reversed by LTL ($P = 0.0487$; Fig. 1B).

LTL suppresses LPS-induced cardiomyocyte hypertrophy and formation of autophagosomes. In order to prove the role of LTL on cardiomyocyte hypertrophy and formation of autophagosomes, cultured cardiomyocytes were treated with PBS, FBS, LPS, LTL1 and LPS, and LTL2 and LPS for 8 h. The expression levels of ANP and BNP were increased by LPS compared with the control ($P < 0.01$; Fig. 1C). Cell size was measured through surface area calculation [(axb)/2] under fluorescence microscopy following anti- α -actinin staining. Data demonstrated that LPS increased α -actinin (a cardiomyocyte specific marker and a hypertrophic marker gene) (31,32) expression levels. However, the effect produced by LPS was reversed by LTL (Myocyte area: From 7.9 to 5.7 μm^2 , $P < 0.05$; From 7.9 to 4.0 μm^2 , $P < 0.01$; Figs. 1C and 2A). It was indicated that LTL suppressed LPS-induced cardiomyocyte hypertrophy. Similarly, by observing the specific green fluorescence labeling at the autophagosome membranes (LC3II) and the cytoplasmic labeling (LC3I), and quantifying the amount of




Figure 1. LTL increases the viability of rat cardiomyocytes treated with LPS. Cells were divided into five groups, including PBS (control group), 10% fetal bovine serum (NC), LPS (100 ng/ml), LTL1 (50 mg/ml) + LPS (100 ng/ml), and LTL2 (100 mg/ml) + LPS (100 ng/ml) for 8 h. (A) The morphology of the cultured rat cardiomyocytes (24 h). (B) Cell viability was detected by the MTT assay. (C) Expression levels of ANP and BNP was determined by reverse transcription-quantitative polymerase chain reaction. * $P < 0.05$ and ** $P < 0.01$ vs. NC; * $P < 0.05$ vs. LPS. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; LC3, microtubule-associated protein 1 light chain 3; LPS, lipopolysaccharide; LTL, luteolin; NC, negative control.




Figure 2. LTL suppresses LPS-induced cardiomyocyte hypertrophy and formation of autophagosomes. (A) The expression levels of α -actinin (a cardiomyocyte specific marker and a hypertrophic marker gene) were measured by immunofluorescence staining in the treated cardiomyocytes; nuclei were stained with DAPI. The Myocyte area (μm^2) was calculated by formula (axb)/2 (a: The longest distance through the nucleus; b: The shortest distance through the nucleus) and analyzed by Image Pro-Plus 6.1 software after anti- α -actinin staining (green). (B) The expression levels of LC3 (green) were measured by immunofluorescence assay in the treated cardiomyocytes; nuclei were stained with DAPI. By specific labeling of autophagosome membranes (LC3II) and the cytoplasmic labeling (LC3I) and the amount of LC3 was quantified by densitometry. *** $P < 0.001$ vs. NC; ** $P < 0.01$ and *** $P < 0.001$ vs. LPS. LC3, microtubule-associated protein 1 light chain 3; LPS, lipopolysaccharide; LTL, luteolin; NC, negative control.

autophagosomes by densitometry (29,33), it was found that LPS increased LC3 expression levels, which was reversed by LTL, suggesting that LTL suppressed LPS-induced formation of autophagosomes ($P < 0.05$; Fig. 2B).

LTL decreases LPS-mediated autophagy and Wnt signaling pathway-associated genes. In addition, the effects produced by LTL on autophagy-associated genes were further

analyzed. Cardiomyocytes were treated with PBS, FBS, LPS, LTL1 + LPS, or LTL2 + LPS for 8 h. Expression levels of LC3 and autophagy-associated genes (Atg12, Atg4b, Vps34 and Bnip1) were measured by RT-qPCR and western blot assays. Results demonstrated that LC3 expression levels were notably upregulated in the LPS group in comparison with that of the NC group, and that LC3II expression levels were downregulated and LC3I expression was upregulated




Figure 3. LTL decreases LPS-mediated autophagy- and Wnt signaling pathway-associated gene expression levels. (A) RT-qPCR and (B) western blot assays were performed to detect the LC3 mRNA and LC3I and II protein expression levels, respectively. (C and D) Autophagy-associated gene expression levels were analyzed by RT-qPCR and western blot assays. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ vs. NC; ** $P < 0.01$ and *** $P < 0.001$ vs. LPS. Atg, autophagy-related 4b cysteine peptidase; Bnip, B cell lymphoma 12 interacting protein; LC3, microtubule-associated protein 1 light chain 3; LPS, lipopolysaccharide; LTL, luteolin; NC, negative control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

in both LTL + LPS groups, compared with the LPS alone group ($P < 0.05$; Fig. 3A and B). However, LPS promoted autophagy-associated gene (Atg12, protein level of Atg4b, Vps34 and Bnip1) expression levels, which was then inhibited by LTL ($P < 0.05$; Fig. 3C and D). LTL exhibited an abnormal effect on the mRNA expression of Atg4b in that low concentrations of LTL demonstrated a promoting effect and high concentrations of LTL demonstrated an inhibitory effect. This finding requires further research.

Wnt/ β -catenin signaling pathway serves a conservative signaling pathway, and exists in various organisms (34,35). In addition, Wnt/ β -catenin signaling pathway serves a dual role in the process of heart development (36,37). In the present study, the expression levels of Wnt signaling pathway-associated genes were investigated (Wnt2, β -catenin and p-GSK3 β) using RT-qPCR and western blot assays. LPS significantly increased the expression levels of Wnt2, β -catenin and p-GSK3 β ,

however, such an increase was inhibited by LTL ($P < 0.05$; Fig. 3E and F).

β -catenin expression is silenced using siRNAs in cardiomyocytes. As shown in previous results, LTL decreased LPS-mediated Wnt signaling pathway-associated genes. The knockdown efficiency of β -catenin in cardiomyocytes using RT-qPCR and western blot assays was established. The results indicated that the mRNA expression levels of β -catenin were decreased in si- β -catenin group compared with that of control group ($P < 0.05$; Fig. 4A). Western blot results demonstrated that in comparison with the NC group, the protein expression levels of β -catenin decreased notably in the si- β -catenin group ($P < 0.05$; Fig. 4B and C).

Silencing of β -catenin inhibits LPS-induced cardiomyocyte hypertrophy and formation of autophagosomes. To further




Figure 3. Continued. LTL decreases LPS-mediated autophagy- and Wnt signaling pathway-associated gene expression levels. (E and F) Wnt signal pathway associated genes expression levels were detected by RT-qPCR and western blot assays. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ vs. NC; ** $P < 0.01$ and *** $P < 0.001$ vs. LPS. Atg, autophagy-related 4b cysteine peptidase; Bnip, B cell lymphoma 12 interacting protein; LC3, microtubule-associated protein 1 light chain 3; LPS, lipopolysaccharide; LTL, luteolin; NC, negative control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

investigate the exact roles of β -catenin in LPS-induced cardiomyocyte hypertrophy and the formation of autophagosomes in them, cardiomyocytes were treated with PBS, FBS, LPS, β -catenin siRNAs + LPS, and β -catenin siRNAs + LTL1 + LPS for 8 h. Immunofluorescence staining was then performed to measure the expression levels of α -actinin and LC3. The results demonstrated that LPS induced α -actinin expression levels, which was then reversed by silencing β -catenin by siRNA (From 7.5-5.5 μm^2) and by si β -catenin with LTL1 co-treatment (From 7.5-5.0 μm^2). This may suggest that silencing of β -catenin and si β -catenin with LTL1 co-treatment suppressed LPS-induced cardiomyocyte hypertrophy ($P < 0.05$; Fig. 5A). Similarly, LPS was observed to increase LC3 expression levels, which was then reversed by the silencing of β -catenin and by si β -catenin with LTL1 co-treatment, suggesting this may have inhibited LPS-induced formation of autophagosomes ($P < 0.05$; Fig. 5B). Though there is no difference in the effects of siRNA with or without LTL1 co-treatment, the inhibitory effects of LTL1 co-treatment with siRNA was slightly stronger compared with siRNA treatment alone. If the concentration of LTL is increased, the inhibitory effects may be more pronounced and this needs to be investigated further.

Discussion

Lipopolysaccharide (LPS) is a category of glycolipids composed of two distinct regions, and LPS can lead to endotoxemia induced by infections with gram-negative

bacteria (38-40). Cardiac hypertrophy is an adaptive mechanism of the heart, which can strengthen cardiac output in certain physiological and pathological conditions (41). Previous studies showed that LPS could cause cardiac dysfunction through cardiomyocytes apoptosis, activation of inflammation or necrosis (8-10).

Autophagy, as a cellular degradation system, mainly participates in removing redundancy or damaged organelles, and longevous proteins and cell components (42). At first, isolated membrane or phagophore of cytoplasm can form autophagosome (43,44). Subsequently, autophagosomes fuse with lysosomes, forming autolysosomes. The contents are then dissolved by the lysosomal hydrolytic enzymes (45). A previous study also demonstrated that autophagy may occur in particular situations, such as oxidative stress, chemical agent's induction, nutrient deprivation, immune cell activation, cellular and tissue remodeling (42-46). Previous studies have indicated that autophagy was closely associated with immune processes (46,47). In addition, autophagy can be assessed by some markers, such as LC3, Atg, Bnip1 and Vps34 (48-50). Among them, LC3 is a common autophagy-associated marker (33). Previous studies have also shown that LPS-induced autophagy can participate in a variety of biological processes (51,52). Therefore, LPS was selected in the present study to induce hypertrophy and autophagy in cardiac myocytes.

LTL can reduce the mortality of coronary heart disease and has a protective effect on cardiovascular disease (53). Furthermore, some studies demonstrated that LTL repressed




Figure 4. β-Catenin expression is silenced using siRNA in cardiomyocytes. (A) Reverse transcription-quantitative polymerase chain reaction and (B) western blot assays were performed to detect the knockdown efficiency of β-catenin siRNA. (C) Quantification of the western blot analysis from (B). **P<0.01 and ***P<0.001 vs. NC. NC, normal control; siRNA, small interfering RNA.




Figure 5. Silencing of β-catenin inhibits LPS-induced cardiomyocyte hypertrophy and formation of autophagosome. (A) Expression levels of α-actinin (a cardiomyocyte specific marker and a hypertrophic marker gene) were measured by immunofluorescence staining; nuclei were stained with DAPI. The myocyte area was calculated by formula (axb)/2 (a: The longest distance through the nucleus; b: The shortest distance through the nucleus) and analyzed by Image Pro-Plus 6.1 software after anti-α-actinin staining (green). (B) LC3 expression levels were measured by immunofluorescence assay; nuclei were stained with DAPI. By specific labeling of autophagosome membranes (LC3II) and the cytoplasmic labeling (LC3I) and the amount of LC3 was quantified by densitometry. ***P<0.001 vs. NC; *P<0.05 vs. LPS. LC3, microtubule-associated protein 1 light chain 3; LPS, lipopolysaccharide; LTL, luteolin; NC, normal control; siRNA, small interfering RNA.

ischemia/reperfusion-induced myocardial damage in cardiomyocytes (54,55). However, the roles of LTL on LPS-induced cardiomyocyte hypertrophy and the formation of autophagosomes in cardiomyocytes were not entirely clear. The present study results found that LPS significantly decreased the viability of rat cardiomyocytes, and that the cell viability of rat cardiomyocytes was recovered when the cells were treated with LTL. In addition, the role of LTL on cardiomyocyte hypertrophy and the formation of autophagosomes was investigated, and it was found that LPS increased α -actinin and LC3 expression levels that were then reversed by LTL. This suggested that LTL suppressed LPS-induced cardiomyocyte hypertrophy and the formation of autophagosomes. The effects produced by LTL on autophagy-associated genes was also investigated. The present results demonstrated that LPS promoted LC3 and autophagy-associated genes (Atg12, Atg4b, Vps34 and Bnip1) expression levels but this was inhibited by LTL. Therefore, it may be suggested that LTL inhibited the LPS-induced cell viability, cardiomyocyte hypertrophy and the formation of autophagosomes in rat cardiomyocytes, but this needs to be investigated further.

Wnt signaling pathway largely serves essential roles in various biological processes (56-58). β -Catenin is a central mediator in this signaling pathway regulated by Wnt proteins, contributing to the development of various diseases, such as cancer, nephropathy, diabetes, Alzheimer's disease and nerve disease (59-61). Previous studies have demonstrated that Wnt signaling pathway can be activated by silencing GSK3 β expression in human adipose stem cells (62). Previous studies have demonstrated that Wnt signaling pathway is involved, for example, in the regulation of cardiomyocyte regeneration, injury, hypertrophy (63-65). Hence, LPS might induce the hypertrophy and autophagy of cardiomyocytes via modulating Wnt signaling pathway. As expected, it was found that LPS induced the hypertrophy and autophagy of cardiomyocytes via stimulating Wnt pathway, however, LTL suppressed this pathway modulated by LPS. In addition, β -catenin silencing notably reduced LPS-induced hypertrophy and the formation of autophagosomes of cardiomyocytes.

In summary, the data obtained in the present study indicated that LTL increased the viability of cardiomyocytes treated by LPS, and that LTL inhibited cardiomyocyte hypertrophy and the formation of autophagosomes of rat cardiomyocytes induced by LPS. LTL decreased Wnt signaling pathway mediated by LPS, and silencing of β -catenin inhibited LPS-induced cardiomyocyte hypertrophy and the formation of autophagosomes. Therefore, it may be concluded that LTL may contribute to LPS-induced cardiomyocyte hypertrophy and autophagy in cardiomyocytes by regulating β -catenin, but this needs to be verified.

Acknowledgements

Not applicable.

Funding

The present study was supported by State Traditional Chinese Medicine Base Construction Project No. JDZX2015143 under State Administration of Traditional Chinese Medicine.

Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

Authors' contributions

XL designed the study, JL and JW performed the experiments, DZ and JW analyzed the data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests.

The authors declare that they have no competing interests.

References

- Viau DM, Sala-Mercado JA, Spranger MD, O'Leary DS and Levy PD: The pathophysiology of hypertensive acute heart failure. *Heart* 101: 1861-1867, 2015.
- Buglioni A and Burnett JC Jr: Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: Biomarkers or mediators. *Clin Chim Acta* 443: 3-8, 2015.
- Phinikaridou A, Andia ME, Shah AM and Botnar RM: Advances in molecular imaging of atherosclerosis and myocardial infarction: Shedding new light on in vivo cardiovascular biology. *Am J Physiol Heart Circ Physiol* 303: H1397-1410, 2012.
- Chien KR: Molecular advances in cardiovascular biology. *Science* 260: 916-917, 1993.
- Cui S, Cui Y, Li Y, Zhang Y, Wang H, Qin W, Chen X, Ding S, Wu D and Guo H: Inhibition of cardiac hypertrophy by aromadendrin through down-regulating NFAT and MAPKs pathways. *Biochem Biophys Res Commun* 506: 805-811, 2018.
- Karkhanis YD, Zeltner JY, Jackson JJ and Carlo DJ: A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. *Anal Biochem* 85: 595-601, 1978.
- Ishizuya-Oka A, Kajita M and Hasebe T: Thyroid hormone-regulated Wnt5a/Ror2 signaling is essential for dedifferentiation of larval epithelial cells into adult stem cells in the *Xenopus laevis* intestine. *PLoS One* 9: e107611, 2014.
- Cheng PY, Lee YM, Wu YS, Chang TW, Jin JS and Yen MH: Protective effect of baicalein against endotoxic shock in rats in vivo and in vitro. *Biochem Pharmacol* 73: 793-804, 2007.
- Lee YM, Cheng PY, Chim LS, Kung CW, Ka SM, Chung MT and Sheu JR: Baicalein, an active component of *Scutellaria baicalensis* Georgi, improves cardiac contractile function in endotoxaemic rats via induction of heme oxygenase-1 and suppression of inflammatory responses. *J Ethnopharmacol* 135: 179-185, 2011.
- Lancel S, Joulin O, Favory R, Goossens JF, Kluza J, Chopin C, Formstecher P, Marchetti P and Neviere R: Ventricular myocyte caspases are directly responsible for endotoxin-induced cardiac dysfunction. *Circulation* 111: 2596-2604, 2005.
- Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, *et al*: Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. *Circ Res* 102: 257-264, 2008.
- Baumgarten G, Kim SC, Stapel H, Vervölgyi V, Bittig A, Hoeft A, Meyer R, Grohé C and Knuefermann P: Myocardial injury modulates the innate immune system and changes myocardial sensitivity. *Basic Res Cardiol* 101: 427-435, 2006.
- Mizushima N and Komatsu M: Autophagy: Renovation of cells and tissues. *Cell* 147: 728-741, 2011.

14. Mehrpour M, Esclatine A, Beau I and Codogno P: Autophagy in health and disease. 1. Regulation and significance of autophagy: An overview. *Am J Physiol Cell Physiol* 298: C776-C785, 2010.
15. Iida T, Onodera K and Nakase H: Role of autophagy in the pathogenesis of inflammatory bowel disease. *World J Gastroenterol* 23: 1944-1953, 2017.
16. Kizilarlanoglu MC and Ülger Z: Role of autophagy in the pathogenesis of Alzheimer disease. *Turk J Med Sci* 45: 998-1003, 2015.
17. Ryter SW and Choi AM: Autophagy in lung disease pathogenesis and therapeutics. *Redox Biol* 4: 215-225, 2015.
18. Denton D, Nicolson S and Kumar S: Cell death by autophagy: Facts and apparent artefacts. *Cell Death Differ* 19: 87-95, 2012.
19. Turdi S, Han X, Huff AF, Roe ND, Hu N, Gao F and Ren J: Cardiac-specific overexpression of catalase attenuates lipopolysaccharide-induced myocardial contractile dysfunction: Role of autophagy. *Free Radic Biol Med* 53: 1327-1338, 2012.
20. Nabavi SF, Braidyn N, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Wozniak K and Nabavi SM: Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. *Brain Res Bull* 119: 1-11, 2015.
21. Li J, Deng LL, Zhou ZY, Yuan D, Zhang CC and Wang T: Protective effect of total saponins of *Panax notoginseng* combined with total flavonoids of epimedium on D-galactose-induced senescence of H9c2 cell. *Zhongguo Zhong Yao Za Zhi* 42: 555-561, 2017 (In Chinese).
22. Wei ZC, Tong D, Yang J, Zhao KH, Meng XL and Zhang Y: Action mechanism of total flavonoids of *Hippophae rhamnoides* in treatment of myocardial ischemia based on network pharmacology. *Zhongguo Zhong Yao Za Zhi* 42: 1238-1244, 2017 (In Chinese).
23. Tan X, Liu B, Lu J, Li S, Baiyun R, Lv Y, Lu Q and Zhang Z: Dietary luteolin protects against HgCl₂-induced renal injury via activation of Nrf2-mediated signaling in rat. *J Inorg Biochem* 179: 24-31, 2018.
24. Tsai CH, Tzeng SF, Hsieh SC, Yang YC, Hsiao YW, Tsai MH and Hsiao PW: A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. *Sci Rep* 7: 15624, 2017.
25. Wu G, Li J, Yue J, Zhang S and Yunusi K: Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma. *Mol Med Rep* 17: 2456-2464, 2018.
26. Simpson P: Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. *J Clin Invest* 72: 732-738, 1983.
27. Simpson P, McGrath A and Savion S: Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. *Circ Res* 51: 787-801, 1982.
28. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
29. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J* 19: 5720-5728, 2000.
30. Zhang J, Liu L, Xue Y, Ma Y, Liu X, Li Z, Li Z and Liu Y: Endothelial monocyte-activating polypeptide-II induces BNIP3-mediated mitophagy to enhance temozolomide cytotoxicity of glioma stem cells via down-regulating MiR-24-3p. *Front Mol Neurosci* 11: 92, 2018.
31. Wang YS, Zhou J, Hong K, Cheng XS and Li YG: MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase. *Cell Physiol Biochem* 35: 1546-1556, 2015.
32. Giguère H, Dumont AA, Berthiaume J, Oliveira V, Laberge G and Auger-Messier M: ADAP1 limits neonatal cardiomyocyte hypertrophy by reducing integrin cell surface expression. *Sci Rep* 8: 13605, 2018.
33. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y and Yoshimori T: LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. *J Cell Sci* 117: 2805-2812, 2004.
34. Yang Y: Wnt signaling in development and disease. *Cell Biosci* 2: 14, 2012.
35. Cadigan KM and Peifer M: Wnt signaling from development to disease: Insights from model systems. *Cold Spring Harb Perspect Biol* 1: a002881, 2009.
36. Naito AT, Shiojima I, Akazawa H, Hidaka K, Morisaki T, Kikuchi A and Komuro I: Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis. *Proc Natl Acad Sci USA* 103: 19812-19817, 2006.
37. Lian X, Zhang J, Zhu K, Kamp TJ and Palecek SP: Insulin inhibits cardiac mesoderm, not mesendoderm, formation during cardiac differentiation of human pluripotent stem cells and modulation of canonical Wnt signaling can rescue this inhibition. *Stem Cells* 31: 447-457, 2013.
38. Liu CJ, Cheng YC, Lee KW, Hsu HH, Chu CH, Tsai FJ, Tsai CH, Chu CY, Liu JY, Kuo WW and Huang CY: Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardial cells. *Mol Cell Biochem* 313: 167-178, 2008.
39. Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL and Godowski PJ: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. *Nature* 395: 284-288, 1998.
40. Yasuda S and Lew WY: Lipopolysaccharide depresses cardiac contractility and beta-adrenergic contractile response by decreasing myofilament response to Ca²⁺ in cardiac myocytes. *Circ Res* 81: 1011-1020, 1997.
41. Frey N, Katus HA, Olson EN and Hill JA: Hypertrophy of the heart: A new therapeutic target? *Circulation* 109: 1580-1589, 2004.
42. Levine B, Mizushima N and Virgin HW: Autophagy in immunity and inflammation. *Nature* 469: 323-335, 2011.
43. Mizushima N: Autophagy: Process and function. *Genes Dev* 21: 2861-2873, 2007.
44. Klionsky DJ: Autophagy: From phenomenology to molecular understanding in less than a decade. *Nat Rev Mol Cell Biol* 8: 931-937, 2007.
45. Kamada Y, Sekito T and Ohsumi Y: Autophagy in yeast: A TOR-mediated response to nutrient starvation. *Curr Top Microbiol Immunol* 279: 73-84, 2004.
46. Levine B and Klionsky DJ: Development by self-digestion: Molecular mechanisms and biological functions of autophagy. *Dev Cell* 6: 463-477, 2004.
47. Kuballa P, Nolte WM, Castoreno AB and Xavier RJ: Autophagy and the immune system. *Annu Rev Immunol* 30: 611-646, 2012.
48. Prokesh A, Blaschitz A, Bauer T, Moser G, Hiden U, Zadora J, Dechend R, Herse F and Gauster M: Placental DAPK1 and autophagy marker LC3B-II are dysregulated by TNF- α in a gestational age-dependent manner. *Histochem Cell Biol* 147: 695-705, 2017.
49. Chen S, Jiang YZ, Huang L, Zhou RJ, Yu KD, Liu Y and Shao ZM: The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. *Clin Cancer Res* 19: 6853-6862, 2013.
50. Zhu Q and Lin F: Molecular markers of autophagy. *Yao Xue Xue Bao* 51: 33-38, 2016 (In Chinese).
51. Qin L, Wang X, Zhang S, Feng S, Yin L and Zhou H: Lipopolysaccharide-induced autophagy participates in the control of pro-inflammatory cytokine release in grass carp head kidney leukocytes. *Fish Shellfish Immunol* 59: 389-397, 2016.
52. Yang X, Jing T, Li Y, He Y, Zhang W, Wang B, Xiao Y, Wang W, Zhang J, Wei J and Lin R: Hydroxytyrosol attenuates LPS-induced acute lung injury in mice by regulating autophagy and sirtuin expression. *Curr Mol Med* 17: 149-159, 2017.
53. Luo Y, Shang P and Li D: Luteolin: A flavonoid that has multiple cardio-protective effects and its molecular mechanisms. *Front Pharmacol* 8: 692, 2017.
54. Bian C, Xu T, Zhu H, Pan D, Liu Y, Luo Y, Wu P and Li D: Luteolin inhibits ischemia/reperfusion-induced myocardial injury in rats via downregulation of microRNA-208b-3p. *PLoS One* 10: e0144877, 2015.
55. Fang F, Li D, Pan H, Chen D, Qi L, Zhang R and Sun H: Luteolin inhibits apoptosis and improves cardiomyocyte contractile function through the PI3K/Akt pathway in simulated ischemia/reperfusion. *Pharmacology* 88: 149-158, 2011.
56. Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. *Science* 303: 1483-1487, 2004.
57. Holland JD, Klaus A, Garratt AN and Birchmeier W: Wnt signaling in stem and cancer stem cells. *Curr Opin Cell Biol* 25: 254-264, 2013.
58. Clevers H: The cancer stem cell: Premises, promises and challenges. *Nat Med* 17: 313-319, 2011.
59. Godoy JA, Rios JA, Zolezzi JM, Braidyn N and Inestrosa NC: Signaling pathway cross talk in Alzheimer's disease. *Cell Commun Signal* 12: 23, 2014.
60. Zhan T, Rindtorff N and Boutsos M: Wnt signaling in cancer. *Oncogene* 36: 1461-1473, 2017.
61. Stylianidis V, Hermans KCM and Blankesteyn WM: Wnt Signaling in Cardiac Remodeling and Heart Failure. *Handb Exp Pharmacol* 243: 371-393, 2017.

62. Huang J, Guo X, Li W and Zhang H: Activation of Wnt/ β -catenin signalling via GSK3 inhibitors direct differentiation of human adipose stem cells into functional hepatocytes. *Sci Rep* 7: 40716, 2017.
63. Ozhan G and Weidinger G: Wnt/ β -catenin signaling in heart regeneration. *Cell Reg (Lond)* 4: 3, 2015.
64. Sassi Y, Avramopoulos P, Ramanujam D, Gräter L, Werfel S, Giosele S, Brunner AD, Esfandyari D, Papadopoulou AS, De Strooper B, *et al*: Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. *Nat Commun* 8: 1614, 2017.
65. Yu L, Meng W, Ding J and Cheng M: Klotho inhibits angiotensin II-induced cardiomyocyte hypertrophy through suppression of the AT1R/ β catenin pathway. *Biochem Biophys Res Commun* 473: 455-461, 2016.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.